Although the effectiveness of these and other approaches on animal models or humans, remains to be investigated, the suppression of snRNP hypo-assembly and splicing defects may provide benefits to SMA patients beyond the benefit of SMN restoration alone. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.